0001438533-21-000045.txt : 20210917 0001438533-21-000045.hdr.sgml : 20210917 20210916211759 ACCESSION NUMBER: 0001438533-21-000045 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210914 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210917 DATE AS OF CHANGE: 20210916 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Travere Therapeutics, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262383102 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 211259095 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 888-969-7879 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Retrophin, Inc. DATE OF NAME CHANGE: 20130220 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 8-K 1 tvtx-20210914.htm 8-K tvtx-20210914

Washington, D.C. 20549
Current Report
Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 14, 2021
(Exact name of registrant as specified in its charter)

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
3611 Valley Centre Drive, Suite 300
San Diego, CA 92130
(Address of Principal Executive Offices, including Zip Code)

(888) 969-7879
(Registrant’s Telephone Number, including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per share
The Nasdaq Global Market

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Principal Accounting Officer

On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved the appointment of Sandra Calvin as the Company’s principal accounting officer, effective September 15, 2021. In connection with the appointment, Ms. Calvin’s new title is Vice President, Corporate Controller and Chief Accounting Officer. Ms. Calvin will assume the principal accounting officer duties from Laura Clague and Ms. Clague will retain her duties as Chief Financial Officer and principal financial officer.

Ms. Calvin, 56, has served as the Company’s Vice President, Corporate Controller since April 2018. From December 2014 through March 2018, she served as the Company’s Executive Director, Corporate Controller. From August 2012 to October 2014 she served as Director and San Diego Site Controller for Amylin Pharmaceuticals LLC, a wholly-owned subsidiary first of Bristol-Myers Squibb and then of Astrazeneca during such period. From 2004 to 2012 she held positions of increasing responsibility within the finance department of Amylin Pharmaceuticals, Inc., a publicly-traded biotechnology company prior to its acquisition by Bristol-Myers Squibb and from 1990 to 2004 she held positions of increasing responsibility within the finance department of Vical Incorporated, a publicly-traded biotechnology company. Earlier in her career Ms. Calvin was a staff auditor with Deloitte & Touche LLP. Ms. Calvin is a Certified Public Accountant (currently inactive) and holds a Bachelor of Science in Business Administration, with an emphasis in Accounting, from San Diego State University.

Item 9.01    Financial Statements and Exhibits.
(d) Exhibits
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 17, 2021   By:/s/ Elizabeth E. Reed
      Name:Elizabeth E. Reed
Title:Senior Vice President, General Counsel and Secretary

EX-101.SCH 2 tvtx-20210914.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 tvtx-20210914_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 4 tvtx-20210914_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 tvtx-20210914_htm.xml IDEA: XBRL DOCUMENT 0001438533 2021-09-14 2021-09-14 0001438533 false 8-K 2021-09-14 TRAVERE THERAPEUTICS, INC. DE 001-36257 27-4842691 3611 Valley Centre Drive Suite 300 San Diego CA 92130 888 969-7879 false false false false false Common Stock, par value $0.0001 per share TVTX NASDAQ XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Sep. 14, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Sep. 14, 2021
Entity Central Index Key 0001438533
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-36257
Entity Tax Identification Number 27-4842691
Entity Address, Address Line One 3611 Valley Centre Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 888
Local Phone Number 969-7879
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol TVTX
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.travere.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tvtx-20210914.htm tvtx-20210914.xsd tvtx-20210914_lab.xml tvtx-20210914_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tvtx-20210914.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tvtx-20210914.htm" ] }, "labelLink": { "local": [ "tvtx-20210914_lab.xml" ] }, "presentationLink": { "local": [ "tvtx-20210914_pre.xml" ] }, "schema": { "local": [ "tvtx-20210914.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tvtx", "nsuri": "http://www.travere.com/20210914", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tvtx-20210914.htm", "contextRef": "iaad590fdc1c6494eaac54595b9dbbcf6_D20210914-20210914", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.travere.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tvtx-20210914.htm", "contextRef": "iaad590fdc1c6494eaac54595b9dbbcf6_D20210914-20210914", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.travere.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001438533-21-000045-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001438533-21-000045-xbrl.zip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end